Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell Therapy

Transplantation and Cellular Therapy(2020)10.1016/j.jtct.2020.10.022Source: DataRank Database

The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell Therapy is a research paper published in Transplantation and Cellular Therapy (2020). On theSindex it has a DataRank of 0. It has been cited 47 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access47 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (14 grants)Impact (FWCI 1.75)OA: greenTopics (31)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (22)

Kitsada Wudhikarn ORCID,Martina Pennisi ORCID,Rosalía Alonso ORCID,Jessica Flynn ORCID,Roni Shouval ORCID

Live enrichment

PubMed:33781518 PMC:PMC8010220 OpenAlex:https://openalex.org/W3116823573

NCI NIH HHS

Grant: P30 CA008748

American Society for Transplantation and Cellular Therapy

Bayer Fund

National Institutes of Health

Astellas Pharma US

Merck

AbbVie

Amgen

Novartis

Bristol-Myers Squibb

Miltenyi Biotec

American-Italian Cancer Foundation

Janssen Pharmaceuticals

Parker Institute for Cancer Immunotherapy

FWCI

1.75

Citation Percentile

0.9%

Citation Trend

2021

2022

2023

2024

2025

2026

greenLicense: http://creativecommons.org/licenses/by-nc-nd/4.0/

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8010220

publisherhttps://api.elsevier.com/content/article/PII:S2666636720300336?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2666636720300336?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jtct.2020.10.022

Fields of Study

CAR-T cell therapy researchIntegrated Circuits and Semiconductor Failure AnalysisAdvancements in Semiconductor Devices and Circuit DesignCell- and Tissue-Based TherapyHumansImmunotherapy, AdoptiveLymphoma, Large B-Cell, DiffusePrognosisReceptors, Chimeric Antigen

MeSH Terms

Receptors, Chimeric AntigenHumansPrognosisImmunotherapy, AdoptiveLymphoma, Large B-Cell, DiffuseCell- and Tissue-Based Therapy

Keywords

International Prognostic IndexMedicineDiffuse large B-cell lymphomaOncologyInternal medicineChimeric antigen receptorCytokine release syndromeHematopoietic stem cell transplantationRituximabLymphomaTransplantationCancerImmunotherapyNon-hodgkin LymphomaCellular TherapyChimeric Antigen Receptor T Cells

Sustainable Development Goals

SDG 0: Good health and well-being